Immuno modulator-1
Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2757469-20-6
- 分子式: C32H31FN6O4
- 分子量:582.62
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
|
IL-2 |
体外実験
Immuno modulator-1 (compound 22) inhibits the proliferation of NCI-H929 human myeloma cell, with an IC50 of 0.6 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats[1]
-
Dosage:1 mg/kg (IV), 5 mg/kg (PO)
-
Administration:IV (2 mL/kg), PO (10 mL/kg); once (Pharmacokinetic Analysis)
-
Result:Pharmacokinetic Parameters of Immuno modulator-1 in male Sprague-Dawley rats[1].
IV (1 mg/kg) PO (5 mg/kg) Cmax (ng/mL) 1437 AUC0-24 (ng/mL∗h) 13029 CL (mL/min/kg) 2.2 Vss (L/kg) 0.36 F (%) 30%
化学情報
-
CAS 番号 2757469-20-6
-
分子量 582.62
-
分子式 C32H31FN6O4
-
SMILES
C[C@@H](N1CCN(C2=C(C=C(C=N2)C#N)F)CC1)C(C=C3)=CC=C3COC4=C5C(C(N([C@@H]6C(NC(CC6)=O)=O)C5)=O)=CC=C4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PBMC Thawing for Immune Assays
PBMC thawing for immune assays recovers viable cryopreserved peripheral blood mononuclear cells for downstream functional or phenotypic readouts, including ELISPOT, intracellular cytokine staining, proliferation assays, and flow-cytometric immunophenotyping. Cryopreserved PBMCs can support immune monitoring because antigen-specific T-cell function and major CD4/CD8 phenotypes may be retained after optimized freezing and thawing, although some lymphocyte subsets and activation or memory markers can be altered by cryopreservation. The technical objective is rapid warming of the frozen vial followed by controlled dilution and removal of DMSO-containing cryomedium, because thawing and wash conditions measurably affect viable PBMC recovery and downstream assay performance. Viability alone is insufficient for protocol evaluation because high viability may occur with low live-cell recovery, so both viable percentage and absolute live-cell recovery should be measured after thawing.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)